ArticleJournal of biomedical optics2025
Evaluation of a near-infrared version of TMR-PEG1k, a high-performance untargeted contrast agent for fluorescence-guided surgery, using fluorescence cryotomography.
Article in Journal of biomedical optics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Significance: In previous studies, we reported on a new untargeted contrast agent, TMR-PEG1k, that exhibits high and durable diagnostic performance in glioma models starting within minutes of administration. This agent uses a fluorophore in the visible regime, which, although it helps ensure high-resolution imaging of superficial tissue, precludes the detection of subsurface structures due to the limited optical penetration. Thus, development of a near-infrared (NIR) version of the agent that retains the properties of TMR-PEG1k would combine the favorable diagnostic performance of TMR-PEG1k with sensitivity to subsurface pathologies enabled by NIR imaging. Aim: We aim to determine whether exchanging the fluorophore on TMR-PEG1k from tetramethylrhodamine to cyanine 7 would retain the highly favorable imaging properties exhibited by TMR-PEG1k. Approach: Mice ( Results: Although the imaging system exhibited higher sensitivity to Cy7-PEG1k in phantoms, the 3D cryotomography results showed dramatic differences in the properties of the two agents Conclusions: Cy7-PEG1k did not retain the favorable properties exhibited by TMR-PEG1k and thus is not a suitable NIR analog for this agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.